Lurbinectedin in FET-Fused Tumors | MicrobiomeTrials← Back to trialsNCT05918640
Lurbinectedin in FET-Fused Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-07-27Est. Completion: 2028-07-30
Enrollment target: 63 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Ewing SarcomaColorectal Adenocarcinoma
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant huma…
Scottsdale, United StatesEst. completion Dec 2028
Ewing SarcomaOsteosarcomaSarcomas
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-…
San Francisco, United StatesEst. completion Nov 2027